Related Experiment Video
Updated: Dec 15, 2025

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness
Published on: May 3, 2018
Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis
Shannon K Parr1, Jia Liang2, Keri L Schadler3
1Department of Kinesiology College of Health and Human Sciences Kansas State University Manhattan KS.
Abstract:
Background Cardio-oncology is a clinical discipline focused primarily on the early detection of anticancer therapy-related cardiomyopathy. However, there is growing evidence that the direct adverse consequences extend beyond the myocardium to affect the vasculature, but this evidence remains limited. In addition, there remains a paucity of clinically based strategies for monitoring vascular toxicity in these patients. Importantly, arterial stiffness is increasingly recognized as a surrogate end point for cardiovascular disease and may be an important vascular outcome to consider. Therefore, the aim of this systematic review and meta-analysis was to summarize evidence of increased arterial stiffening with anticancer therapy and evaluate the effect of treatment modifiers. Methods and Results A total of 19 longitudinal and cross-sectional studies that evaluated arterial stiffness both during and following anticancer therapy were identified using multiple databases. Two separate analyses were performed: baseline to follow-up (12 studies) and control versus patient groups (10 studies). Subgroup analysis evaluated whether stiffness differed as a function of treatment type and follow-up time. Standard mean differences and mean differences were calculated using random effect models. Significant increases in arterial stiffness were identified from baseline to follow-up (standard mean difference, 0.890; 95% CI, 0.448-1.332; P<0.0001; mean difference, 1.505; 95% CI, 0.789-2.221; P≤0.0001) and in patient versus control groups (standard mean difference, 0.860; 95% CI, 0.402-1.318; P=0.0002; mean difference, 1.437; 95% CI, 0.426-2.448; P=0.0052). Subgroup analysis indicated differences in arterial stiffness between anthracycline-based and non-anthracycline-based therapies (standard mean difference, 0.20; 95% CI, 0.001-0.41; P=0.048), but not follow-up time. Conclusions Significant arterial stiffening occurs following anticancer therapy. Our findings support the use of arterial stiffness as part of a targeted vascular imaging strategy for the identification of early cardiovascular injury during treatment and for the detection of long-term cardiovascular injury into survivorship.
Insights
Anticancer therapies significantly increase arterial stiffness, a key indicator of cardiovascular disease. This systematic review highlights the need for monitoring vascular health in patients undergoing cancer treatment.
Area of Science:
- Cardio-oncology
- Vascular Medicine
- Oncology
Background:
- Cardio-oncology traditionally focuses on chemotherapy-induced cardiomyopathy.
- Emerging evidence indicates anticancer therapies also cause vascular damage.
- Limited clinical strategies exist for monitoring vascular toxicity in cancer patients.
Purpose of the Study:
- To systematically review and meta-analyze evidence of increased arterial stiffness following anticancer therapy.
- To evaluate the impact of treatment modifiers on therapy-related arterial stiffening.
Main Methods:
- Systematic review and meta-analysis of 19 longitudinal and cross-sectional studies.
- Evaluated arterial stiffness during and after anticancer therapy.
- Performed baseline-to-follow-up and patient-versus-control analyses, with subgroup analysis by treatment type and follow-up time.
Main Results:
- Significant increases in arterial stiffness were observed from baseline to follow-up (SMD 0.890, P<0.0001) and in patients versus controls (SMD 0.860, P=0.0002).
- Arterial stiffness differed significantly between anthracycline-based and non-anthracycline-based therapies (SMD 0.20, P=0.048).
- No significant difference in arterial stiffness was found based on follow-up time.
Conclusions:
- Anticancer therapies lead to significant arterial stiffening.
- Arterial stiffness can serve as a surrogate endpoint for cardiovascular disease in oncology.
- Monitoring arterial stiffness is recommended for early detection of vascular injury during and after cancer treatment.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

